I'm expecting they will be reported as soon as the results for each separate trial are to hand. Each trial is independent and they have slightly different completeion timing because of the different recruitment rates. IMO the Eyelea trial will be the tougher of the two to achieve success because its a more potent drug and superiority will be more difficult even with 990 patients in the trial. On the other hand if the trial is successful that would be a truly remarkable achievement.
Fingers crossed.
Ann: Opthea to Host Key Opinion Leader Event on April 3, 2024, page-12
-
- There are more pages in this discussion • 50 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add OPT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
41.5¢ |
Change
-0.030(6.74%) |
Mkt cap ! $510.9M | |||
| Open | High | Low | Value | Volume |
| 43.0¢ | 43.5¢ | 41.0¢ | $678.4K | 1.623M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 14 | 170578 | 41.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 41.5¢ | 99998 | 1 |
View Market Depth
| Last trade - 16.10pm 30/07/2024 (20 minute delay) ? |
| OPT (ASX) Chart |